Welcome to

TARGEDYS

Our mission is to control metabolic disease by modulating the appetite through an intervention on the microbiome.

WHO ARE WE?

OUR UNIQUE APPROACH

Is to use the concept of molecular mimicry to physiologically bind well-described pharmacological targets with bacterial metabolites and derived small molecules

TargEDys® translates its unique understanding of the gut-brain axis to develop and manufacture nutritional and therapeutic solutions to control metabolic diseases. The company aims to be at the forefront of safe and effective weight management to improve the health and life quality of many over and underweight people.

 

The TargEDys research team at the INSERM lab of Rouen University has identified a novel mechanism of appetite regulation involving bacterial, hormonal mimetic, proteins that are found naturally in the gut microbiome. This mechanism acts as the basis of TargEDys’ two technologies: ProbioSatys™ and ProbioNutrys™, which respectively moderate the appetite of overweight people and restore the appetite of elderly, cachexic or anorexic people.

OUR FOCUS

Overweight

1.4B

people (>20yrs) are overweight
(WHO, 2009)

5th

biggest risk factor for death is obesity
(WHO, 2014)

50%

of the population in France are overweight
(INVS, 2016)

70%

of the US population are affected by obesity and overweight
(OECD, 2017)

13%

of the worldwide adult population are obese
(The Lancet, 2016)
Underweight

70M

people worldwide suffering from eating disorders
(Renfrew, 2003)

3rd

most common chronic illness for adolescents is anorexia
(Yeo&Hughes, 2011)

50-80%

of cancer patients
are affected
by cachexia
(Anker, 2014)

20%

of cancer deaths
are caused
by cachexia
(Takabe, 2015)

30-60%

of elderly
people are
undernourished
(Bozzetti, 2010)

OUR TIMELINE

Our

NEWS

Latest company news and where to find us

8th May, 2019

ProbioSatys WINS NutraIngredients' 2019 Ingredient of the year for Weight Management!

TargEDys innovative ProbioSatys technology has been awarded 'Ingredient of the year for Weight Management' at the NutraIngredients awards.

Read more

March 2019

EnteroSatys in Managers Europe Magazine

EnteroSatys, the new paradigm of TargEDys to fight against obesity

Read more

April, 3rd 2019

EnteroSatys is in Science&Vie Magazine this month

Science & Life puts EnteroSatys in the spotlight in its special issue on the MICROBIOTA!

Read more
See all our news

Technology

& HEALTH

Learn more about our technology

ProbioSatys™ ProbioNutrys™

WHAT IS THE MICROBIOME?

The human microbiome is the genome of our microbes. It is 150 times more diverse than our human genome and formed of 5000-different species of bacteria living all over our bodies, especially our gut, mouth and skin. This symbiotic bacterial community is vital for day-to-day bodily functions such as immunity, defence against pathogens, host nutrition, synthesis of vitamins, fat storage and influencing human behaviour. An imbalance in one’s microbiome has been linked to a range of diseases such as Diabetes, Cancer and Obesity. A key step to unlocking the potential of many microbiome based treatments is to fully understand the microbiome and its interactions with the human host.

WHAT IS THE GUT-BRAIN AXIS?

The gut-brain axis is the bidirectional communication between the central and enteric nervous systems, linking the emotional and cognitive centres of the brain with peripheral intestinal functions. Gut microbiota are very important in influencing these interactions. TargEDys® has discovered a new mechanism of appetite regulation that involves this axis and has developed two types of innovative technology for the treatment of over and underweight patients, ProbioSatys™ and ProbioNutrys™ respectively.

HOW DOES THE MICROBIOME REGULATE YOUR APPETITE?

Watch the video

projects PLATFORM

PROBIOSATYS™

BASED ON HAFNIA ALVEI 4597

Enhancing natural
satiety pathways

After a meal, intestinal bacteria feed on the ingested food and begin to multiply. During this growth phase, the bacteria produce various signals that allow them to interact with the brain. One such signal is the protein ClpB, produced by Enterobacteria naturally present in the intestines. ClpB has been identified as a mimetic of the satiety hormone (α-MSH) that regulates food behaviour at both peripheral and central levels.

When released, ClpB directly stimulates the enteroendocrine L-cells of the intestine to produce satiety hormones. ClpB also enters the bloodstream to act on satiety regulation in the central nervous system by mimicking α-MSH. The resulting effect is the feeling of satiety or fullness after a meal.

KEY BENEFITS

The basis of the ProbioSatys™ technology is an Enterobacteria probiotic strain that produces satiety protein, ClpB.

• Decrease of body weight gain
• Decrease of food intake
• Improvement of body composition
• Activation of lipolysis
• Activation of central satiety pathways

What is
Hafnia alvei 4597?

Hafnia alvei 4597, the probiotic strain used in ProbioSatys®, is a commensal bacterium from the Enterobacteriaceae family, naturally present in the human gut. Hafnia alvei 4597 expresses a protein of interest in the regulation of hunger called caseinolytic peptidase B protein homologue (ClpB). It can also be found in a wide range of traditional foods.

Hafnia alvei was first identified in 1954 in raw milk, and has since been found in traditional cheeses with strong flavours such as Camembert and Livarot. Dairy product contamination during the 1990s led the industrialists to pasteurise their milk, which meant losing the typical aromas appreciated by cheese lovers. Hafnia alvei is now added to pasteurized cheese as a lactic ferment to restore its original flavour.

Hafnia alvei adheres to the intestinal mucosa and resists fasting digestion. It is multiple, and is metabolically active in the colon. Its genome has been fully sequenced and it does not have a plasmid with antibiotic resistance genes. The manufacturing process of Hafnia alvei has been specifically developed for TargEDys.

PROBIONUTRYS™

TargEDys is currently demonstrating the efficacy of another hormone mimetic technology that exploits the gut-brain axis to improve the appetite of anorexic, cachexic or elderly patients.

TRUST YOUR MICROBIOME!

REBALANCE YOUR METABOLISM*

EnteroSatys® contains Hafnia alvei 4597 strain, zinc and chromium which contribute to a healthy metabolic equilibrium*. Hafnia alvei 4597 is a lactic ferment strain, originally isolated from raw milk cheese. The strain has been studied for many years at the National French Medical & Health Research Institute (INSERM) labs in Normandy.
*Zinc contributes to normal lipid and macronutrient metabolism. Chromium contributes to normal blood glucose levels.

To ensure efficacy of the product, EnteroSatys® is manufactured in DRCAPS™ gastro-resistant capsules.

Nutritional composition

Contact us to find out more

Publications &

PRESS

Here are our latest peer reviewed publications, press releases and press articles.

Nature Reviews Endocrinology (2017)

Fetissov, Serguei O.

Role of the Gut Microbiota in Host Appetite Control:
Bacterial Growth to Animal Feeding Behaviour

The life of all animals is dominated by alternating feelings of hunger and satiety — the main involuntary motivations for feeding-related behaviour. Gut bacteria depend fully on their host for providing the nutrients necessary for their growth. […] This Review analyses the data relevant to possible involvement of the gut bacteria in the regulation of host appetite and proposes an integrative homeostatic model of appetite control that includes energy needs of both the host and its gut bacteria.

Read more

The American Journal of Clinical Nutrition (2019)

Marie Galmiche, Pierre Déchelotte, Grégory Lambert, Marie Pierre Tavolacci

« Prevalence of eating disorders over the 2000–2018 period: a systematic literature review ».

Read more

CELL METABOLISM (2016).

Breton, J. et al.

« Gut Commensal E. coli Proteins Activate Host Satiety Pathways following Nutrient - Induced Bacterial Growth ».

Read more

CURRENT MEDICINAL CHEMISTRY (2017).

Fetissov, S. O., R. Legrand, and N. Lucas.

« Bacterial Protein Mimetic of Peptide Hormone as a New Class of Protein - Based Drugs ».

Read more

Press

RELEASES

15th July, 2019

TargEDys announces that BIOCODEX has acquired a share of its capital and appoints new board members.

Read more

January 31, 2019

EnteroSatys® is the first probiotic specifically designed to control appetite. It is composed of Hafnia alvei 4597, supplemented with chromium and zinc and is based on patented molecular mimicry technology. A protein produced by H.alvei imitates α-MSH, a hormone that signals satiety.

Read more

15th November 2018

Neovia signs an R&D partnership with TargEDys and continues to innovate on the petcare market

Read more

2nd July, 2018

Philippe Lavielle appointed Chairman of the TargEDys Board of Directors

Read more

04th April 2017

TargEDys extends Series A and appoints new Board Members.

Read more

9th March 2017

Bpifrance soutient TargEDys et lui octroie une aide pour le développement à l’innovation de 1,1 million d’euros.

Read more

18th July 2016

TargEDys, laureate of the International Innovation Contest (CMI)

Read more

27th June 2016

TargEDys and Inserm Transfert on behalf of Rouen Normandy University and Rouen University Hospital (CHU) sign an exclusive international licensing agreement on a patent portfolio in microbiome-based research.

Read more

14th April 2016

TargEDys develops new microbiome -based solutions for appetite regulation and announces a €5.8M international round of financing to demonstrate product clinical efficacy.

Read more

Our

INVESTORS

TargEDys has completed Series A funding of 10.6 M€ and will begin Series B in 2020.

ABOUT OUR
INVESTORS

NCI is an investment company operating in Normandy and in Ile de France. NCI strives to create sustainable value within its portfolio companies by reconciling finance, economic development and social welfare.

For more details

Pontifax is a venture capital firm focusing on groundbreaking innovations in the life sciences arena. Founded in 2004 and with $350M under management, Pontifax seeks transformative, innovative healthcare opportunities at all development stages.

For more details

With over €660m in assets under management, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies and Life sciences.

For more details

Biocodex is an independent multinational pharmaceutical company built on high-standard science and manufacturing, with six decades of proven success. Founded in 1953, the company’s initial focus was gastroenterology featuring a unique probiotic Saccharomyces boulardii CNCM I-745®, the first probiotic drug of its kind that has a positive effect on the gut’s microflora.

For more details

Our

Team

The main strengths of the team are a very strong Board and Development Committee and CEO with valuable experience running biotech companies, marketing, research and launch products both medical and nutraceutical.

Pierre Déchelotte

Prof, MD, PhD

Founder
Medical Referent

Sergueï Fetissov

Prof, MD, PhD

Founder
Scientific Referent

Grégory Lambert

PhD, Pharm D

CEO and VP R&D

Antonia Trower

BSc

Marketing Manager

Bénédicte Hérate

BA

Office Manager

Clémentine Picolo

Eng

Development
Project Manager

Franck Albert

Senior Consultant

Commercial Manager

Manon Dominique

MSc

PhD Student

Marie Galmiche

Eng

PhD Student

Board of Directors

CEO and VP R&D

Grégory Lambert

Grégory LAMBERT's career has been split between biotech and pharmaceutical companies, in roles such as VP of R&D and General Manager of Novagali Pharma (now Santen) and CSO at Septodont. His responsibilities covered management of IP and business development activities, innovation and CMC as well as pre-clinical and clinical development in Europe and North America. Gregory is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he drove the development of several pharmaceutical products from the laboratory to market authorisations. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations.

Chairman of the Board

PHILIPPE  LAVIELLE

Philippe LAVIELLE is an accomplished entrepreneur. He is currently Chairman and CEO of Fermentalg, a French industrial biotech company specialising in microalgae derived products. Until July 2014 Philippe was President and CEO of Virdia Inc., a biotech company producing carbohydrates from cellulosic biomass. His teams developed one of the world’s most advanced ligno-cellulosic bio-refinery platforms. Prior to joining Virdia, Philippe was Executive Vice President of Genencor Inc., the US based world leader in industrial biotechnology in renewable fuels and bio-chemicals. Philippe is also a Board member of Clara Foods Inc., a US company working towards creating the world’s first animal-free egg white.

Independant Board Member

DANILO  CASADEI-MASSARI

Danilo has extensive experience as a senior pharmaceutical executive and as a highly successful serial entrepreneur. Most recently he was a founder and President of CM&D Pharma Ltd, a medical foods company he founded in 2007 and sold to Nestle Health Science in 2011. He is currently a Director on the boards of companies based in the USA, Italy, Ireland, Finland and France as well as a Cofounder in some of them. Danilo is an expert in start-ups and co-ventures in the pharmaceutical sector.

President & CEO, Seventure Partners

ISABELLE DE CRÉMOUX

Isabelle is President and CEO of Seventure Partners and manages the Life Sciences team. She brings 25 years of international experience in life sciences business development and finance. Isabelle leads the life sciences team and makes direct investments, mainly in France and Scandinavia and in the US/Canada with a focus on biotech, nutrition, personalised medicine and especially microbiome. Isabelle’s track record includes Santaris (sold to Roche for $450 millions in august 2014), Argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience, Maat Pharma and TargEDys.

Venture Partner, Seventure Partners

ERIC DE LA FORTELLE

Eric is Venture Partner with Seventure Partners, a Paris-based venture investor investing broadly in life sciences, with a specific focus on the human microbiome. Seventure closed the first microbiome fund worldwide, called Health for Life, in December 2015. Formerly, Eric was the CEO of a Swiss Biotech company and has led Roche’s global function of External Research and Technologies. Eric is a scientist by training (protein structure determination by X-ray crystallography). He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an MBA (honors) from INSEAD.

CEO, Biocodex

Jean-Marie Lefèvre

Jean-Marie is President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain. Engineering from Ecole Centrale Paris, MBA from Insead

Investment analyst, NCI

LAURIE  PÉRIÉ

Laurie is an investment analyst at NCI, a Normandy -based structure which invests in companies operating in Normandy and in Paris. NCI accompanied more than 130 firms at different stages (VC, LBO, growth capital) and in diverse industries. With a double-digit growth track record, and €180M in managed assets (entrusted by public and private institutional investors), NCI conciliates finance and economic development. Laurie graduated from Rouen Business School in Corporate Finance and passed all the three levels of the CFA Program.

Contact

Us

WHERE TO FIND US?

Office
Zone d'activités Nativelle
Bat 4bis
1 Chemin de Saulxier
91160 Longjumeau
France
Tel: +33 1 72 48 84 57

R&D Laboratories
Faculté de Médecine et de Pharmacie
Bâtiment Recherche - 4ème étage
22 boulevard Gambetta
76183 Rouen
France

Download detailed access plan including car and public transportation Access Plan TargEDys.pdf
Document Adobe Acrobat [198.6 KB]